Joakim Dillner

Joakim Dillner

Professor/Fou-Chef
E-postadress: joakim.dillner@ki.se
Besöksadress: F56 Karolinska Universitetssjukhuset Huddinge, 14186 Stockholm
Postadress: H9 Klinisk vetenskap, intervention och teknik, H9 CLINTEC Centrum för Cervixcancereliminering, 141 52 Huddinge
Del av:

Om mig

  • Jag är professor i infektionsepidemiologi vid KI sedan 2009 och Sektionschef vid molekylär cancerdiagnostik & screening, Medicinsk Diagnostik Karolinska, Karolinska Universitetssjukhuset sedan 2024.. Jag har forskat inom tumörvirologi sedan 1982 och blev professor i virologi 2001. Sedan 1989 har min grupp forskat om Humant Papillomvirus (HPV) inom molekylärbiologi, immunologi och vaccinologi, klinisk virologi och epidemiologi.
    De mest kända projekten är Swedescreen, den första randomiserade HPV-screeningsstudien (sedan 1997), biobank- och registerbaserade uppföljningsstudier av HPV vaccination (sedan 1999), det Internationella Referenscentret för Humant Papillomvirus,  Nationellt Kvalitetsregister för Cervixcancerprevention och det Nationella Projektet för snabbare Utrotning av HPV och livmoderhalscancer i Sverige.


    Utbildning
    Forskarutbildning vid Karolinska Institutet. Disputerade 1986 med avhandlingen ”Identification and Characterization of Epstein-Barr Virus Encoded Proteins in EBV-transformed cells”
    Läkarexamen vid Karolinska Institutet, 1981-1995
    Post-doc 1986-1988 vid Scripps Clinic, La Jolla, Kalifornien
    Docent i virologi, Karolinska Institutet, 1990

    Akademiska priser och utmärkelser
    Ledamot av Cancerfondens Forskningsnämnd 2009-2015
    Ordförande, Nationellt Kvalitetsregister för Cervixcancerprevention
    Årets cancernätverkare 2018 (hedersutmärkelse från Nätverket mot Cancer som innefattar nationella cancerprofilerade patient- och intresseorganisationer i Sverige)

    Eldsjälspriset 2019 från patientföreningen Nätverket mot gynekologisk cancer

Forskningsbeskrivning

  • Min forskning fokuserar på cancerprevention och tumörvirologi, exempelvis prövningar om användning av HPV-testning inom det gynekologiska cellprovtagningsprogrammet och translationella studier om HPV vaccination. Målet med min forskning är att kunna utveckla effektivare program för förebyggande av cancer.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Swedish Research Council
    1 December 2021 - 30 November 2024
  • Translational Studies of Human Papillomavirus
    Swedish Cancer Society
    1 January 2018
    Human Papillomavirus (HPV) is one of the quantitatively most important preventable causes of cancer. WHO estimates that about 5% of all cancers in humans could be eradicated if cancer-causing HPV were eradicated. There are effective vaccines against HPV. There are also tests for HPV which, when used in organized gynecological cell sampling, provide better cancer protection than the old-fashioned cell sample. Our international reference laboratory provides a uniform quality for the detection and classification of HPV, a prerequisite for both basic research and prevention. We analyze the organized cell sampling program and the HPV vaccination program to demonstrate whether there is an opportunity to increase the cancer prevention effect. We hope that the organized gynecological cell sampling program will have an even better preventive effect against cervical cancer. We hope to contribute to an increased understanding of the spread of HPV infections and the medical significance of this. We hope to contribute to the design of a successful elimination of HPV infections through vaccination and thereby to the prevention of HPV-induced cancers.
  • Swedish Research Council
    1 December 2017 - 31 December 2019
  • Translational Studies of Human Papillomavirus
    Swedish Cancer Society
    1 January 2017
    Human Papillomavirus (HPV) is one of the quantitatively most important preventable causes of cancer. WHO estimates that about 5% of all cancers in humans could be eradicated if cancer-causing HPV were eradicated. There are effective vaccines against HPV. There are also tests for HPV which, when used in organized gynecological cell sampling, provide better cancer protection than the old-fashioned cell sample. Our international reference laboratory provides a uniform quality for the detection and classification of HPV, a prerequisite for both basic research and prevention. We analyze the organized cell sampling program and the HPV vaccination program to demonstrate whether there is an opportunity to increase the cancer prevention effect. We hope that the organized gynecological cell sampling program will have an even better preventive effect against cervical cancer. We hope to contribute to an increased understanding of the spread of HPV infections and the medical significance of this. We hope to contribute to the design of a successful elimination of HPV infections through vaccination and thereby to the prevention of HPV-induced cancers.
  • Translational Studies of Human Papillomavirus
    Swedish Cancer Society
    1 January 2016
    Human Papillomavirus (HPV) is today considered one of the quantitatively most important preventable causes of cancer. WHO has estimated that about 5% of all cancers in humans could be eradicated if cancer-causing HPV could be eradicated. There are effective vaccines against HPV. There are also HPV tests that, when used in organized gynecological cell sampling, provide better cancer protection than the old-fashioned cell sample. Finally, there are a large number of HPV viruses that are often found in skin cancer. A large-scale analysis of which HPV types are found in these tumors can provide a good basis for continued research on HPV's role in cancer. Our international reference laboratory provides a uniform quality for the detection and classification of HPV, a prerequisite for both basic research and prevention. We test skin tumors for if they contain HPV. We analyze the organized cell sampling program and the HPV vaccination program, if there is the possibility of increasing the cancer prevention effect. We introduce organized sampling for HPV, in a controlled and evaluable way. We hope that the organized gynecological cell sampling program will have an even better preventive effect against cervical cancer. We hope to contribute to an increased understanding of the extent and role of HPV infections in various tumors. We hope to contribute to the design of a successful elimination of HPV infections through vaccination and thereby to the prevention of HPV-induced cancers.
  • Biobank-based Evaluation of New Cervical Screening Tests
    Swedish Foundation for Strategic Research
    1 January 2015 - 31 December 2019
  • Swedish Research Council
    1 January 2015 - 31 December 2017
  • Translational Studies of Human Papillomavirus
    Swedish Cancer Society
    1 January 2015
    Human Papillomavirus (HPV) is today considered one of the quantitatively most important preventable causes of cancer. WHO has estimated that about 5% of all cancers in humans could be eradicated if cancer-causing HPV could be eradicated. There are effective vaccines against HPV. There are also HPV tests that, when used in organized gynecological cell sampling, provide better cancer protection than the old-fashioned cell sample. Finally, there are a large number of HPV viruses that are often found in skin cancer. A large-scale analysis of which HPV types are found in these tumors can provide a good basis for continued research on HPV's role in cancer. Our international reference laboratory provides a uniform quality for the detection and classification of HPV, a prerequisite for both basic research and prevention. We test skin tumors for if they contain HPV. We analyze the organized cell sampling program and the HPV vaccination program, if there is the possibility of increasing the cancer prevention effect. We introduce organized sampling for HPV, in a controlled and evaluable way. We hope that the organized gynecological cell sampling program will have an even better preventive effect against cervical cancer. We hope to contribute to an increased understanding of the extent and role of HPV infections in various tumors. We hope to contribute to the design of a successful elimination of HPV infections through vaccination and thereby to the prevention of HPV-induced cancers.
  • The Nordic Information for Action eScience Center
    NordForsk
    1 January 2014 - 31 December 2018
  • Translational Studies of Human Papillomavirus
    Swedish Cancer Society
    1 January 2014
    Human Papillomavirus (HPV) is today considered one of the quantitatively most important preventable causes of cancer. WHO has estimated that about 5% of all cancers in humans could be eradicated if cancer-causing HPV could be eradicated. There are effective vaccines against HPV. There are also HPV tests that, when used in organized gynecological cell sampling, provide better cancer protection than the old-fashioned cell sample. Finally, there are a large number of HPV viruses that are often found in skin cancer. A large-scale analysis of which HPV types are found in these tumors can provide a good basis for continued research on HPV's role in cancer. Our international reference laboratory provides a uniform quality for the detection and classification of HPV, a prerequisite for both basic research and prevention. We test skin tumors for if they contain HPV. We analyze the organized cell sampling program and the HPV vaccination program, if there is the possibility of increasing the cancer prevention effect. We introduce organized sampling for HPV, in a controlled and evaluable way. We hope that the organized gynecological cell sampling program will have an even better preventive effect against cervical cancer. We hope to contribute to an increased understanding of the extent and role of HPV infections in various tumors. We hope to contribute to the design of a successful elimination of HPV infections through vaccination and thereby to the prevention of HPV-induced cancers.
  • Swedish Research Council
    1 January 2012 - 31 December 2014

Anställningar

  • Professor/Fou-Chef, Klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2023-
  • Professor/Fou-Chef, Laboratoriemedicin, Karolinska Institutet, 2018-2022
  • Professor/Sjukhuskemist, Laboratoriemedicin, Karolinska Institutet, 2012-2017
  • Professor, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2009-2017
  • Professor, Laboratoriemedicin, Karolinska Institutet, 2009-2012

Examina och utbildning

  • Läkarexamen, Karolinska Institutet, 1995

Nyheter från KI

Kalenderhändelser från KI